Gastrointestinal tolerance of gamma-cyclodextrin in humans.

Saved in:

Bibliographic Details
Title:	Gastrointestinal tolerance of gamma-cyclodextrin in humans.
Authors:	Koutsou, G. A., Storey, D. M., Bar, A.
Source:	Food Additives & Contaminants. Jul99, Vol. 16 Issue 7, p313-317. 5p. 2 Charts.
Subjects:	Cyclodextrins, Food additives
Abstract:	The gastrointenstinal tolerance of gamma-cyclodextrin (gammaCD) was examined in 24 healthy human volunteers. In a double-blind, placebo-controlled, randomized crossover study, single acute doses of 8g maltodextrin (placebo) or 8g gamma-CD (test) were consumed as a mid-morning snack after addition to 100g yogurt. Gastrointenstinal symptoms as well as frequency and consistency of stools were recorded before and after lunch at between 3-4 and 7-8h after intake respectively. The perception of the symptoms was rated on a subjective scale ranging from 1 ('more than normal') to 3('exceptionally more than normal'). Following consumption of maltodextrin, five subjects reported a total of 12 symptoms of which seven, two and three were rated as having grade 1, 2 and 3, respectively. Following consumption of gamma-CD, five subjects reported six symptoms all of which were graded as 1. Two subjects reported flatulence, which is a frequent consequence of the consumption of malabsorbed carbohydrates, after placebo and test treatment. The incidence of individual and combined side-effects as well as the number and consistency of faeces passed was not significantly different between placebo and test treatment. It is concluded that single doses of 8g gamma-CD and maltodextrin are tolerated equally well. This is in keeping with a good digestibility of gamma-CD by salivary and pancreatic amylase. [ABSTRACT FROM AUTHOR]
	Copyright of Food Additives & Contaminants is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database:	Engineering Source

Description
Abstract:	The gastrointenstinal tolerance of gamma-cyclodextrin (gammaCD) was examined in 24 healthy human volunteers. In a double-blind, placebo-controlled, randomized crossover study, single acute doses of 8g maltodextrin (placebo) or 8g gamma-CD (test) were consumed as a mid-morning snack after addition to 100g yogurt. Gastrointenstinal symptoms as well as frequency and consistency of stools were recorded before and after lunch at between 3-4 and 7-8h after intake respectively. The perception of the symptoms was rated on a subjective scale ranging from 1 ('more than normal') to 3('exceptionally more than normal'). Following consumption of maltodextrin, five subjects reported a total of 12 symptoms of which seven, two and three were rated as having grade 1, 2 and 3, respectively. Following consumption of gamma-CD, five subjects reported six symptoms all of which were graded as 1. Two subjects reported flatulence, which is a frequent consequence of the consumption of malabsorbed carbohydrates, after placebo and test treatment. The incidence of individual and combined side-effects as well as the number and consistency of faeces passed was not significantly different between placebo and test treatment. It is concluded that single doses of 8g gamma-CD and maltodextrin are tolerated equally well. This is in keeping with a good digestibility of gamma-CD by salivary and pancreatic amylase. [ABSTRACT FROM AUTHOR]
ISSN:	0265203X
DOI:	10.1080/026520399283984